Prostate cancer organoids lacking both Pten and p53 faithfully recapitulating the aggressive features of advanced diseases,[27, 28] proving a valuable platform for evaluating novel therapeutic strategies. This evidence concerns the gene TP53 and Familial prostate cancer.